PYCARD

Across TCGA pan-cancer cohorts, PYCARD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PYCARD data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PYCARD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PYCARD expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where PYCARD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.653	0.925	.006	26	view →
LSCC	OS	Quartile	All	0.603	0.987	.001	14	view →
GBM	DFS	Tertile	All	0.722	0.896	.014	6	view →
PDAC	DFS	Median	All	0.557	0.332	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PYCARD–CCRCC (DFS)

Open the CCRCC breakdown →